Carboplatin for stage I seminoma [9]

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2971-2972

  Gilligan, Timothy ^a   Oh, William K ^b   Kantoff, Philip W ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; DRUG TOLERABILITY; GERM CELL TUMOR; HEART DEATH; HUMAN; LETTER; LEUKEMIA; METASTASIS; MORTALITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SEMINOMA; TESTIS CANCER; MALE; NOTE; RADIATION INJURY; RISK; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; HUMANS; MALE; NEOPLASMS, RADIATION-INDUCED; RISK; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 33745522511     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.3231     Document Type: Letter

References (21)

1. Loehrer PJ, Bosl GJ: Carboplatin for stage I seminoma and the sword of Damocles. J Clin Oncol 23:8566-8569, 2005
2. Oliver RT, Mason MD, Mead GM, et al: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage 1 seminoma: A randomised trial. Lancet 366:293-300, 2005
3. Aparicio J, Germa JR, del Muro XG, et al: Risk-adapted management for patients with clinical stage I seminoma: The second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23:8717-8723, 2005
4. Aparicio J, Garcia del Muro X, Maroto P, et al: Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14:867-872, 2003
5. Steiner H, Holtl L, Wirtenberger W, et al: Long-term experience with carboplatin monotherapy for clinical stage I seminoma: A retrospective single-center study. Urology 60:324-328, 2002
6. Reiter WJ, Brodowicz T, Alavi S, et al: Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19:101-104, 2001
7. Dieckmann KP, Bruggeboes B, Pichlmeier U, et al: Adjuvant treatment of clinical stage I seminoma: Is a single course of carboplatin sufficient? Urology 55:102-106, 2000
8. Krege S, Kalund G, Otto T, et al: Phase II study: Adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 31:405-407, 1997
9. Dieckmann KP, Krain J, Kuster J, et al: Adjuvant carboplatin treatment for seminoma clinical stage I. J Ca Res Clin Oncol 122:63-66, 1996
10. Schmoll HJ, Harstrick A, Bokemeyer C, et al: Single-agent carboplatinum for advanced seminoma: A phase II study. Cancer 72:237-243, 1993
11. Zagars GK, Ballo MT, Lee AK, et al: Mortality after cure of testicular seminoma. J Clin Oncol 22:640-647, 2004
12. Bokemeyer C, Schmoll HJ: Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11:1703-1709, 1993
13. Travis LB, Curtis RE, Storm H, et al: Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89:1429-1439, 1997
14. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al: Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J Clin Oncol 11:415-424, 1993
15. Wanderas EH, Fossa SD, Tretli S: Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 33:253-262, 1997
16. Travis LB, Fossa SD, Schonfeld SJ, et al: Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97:1354-1365, 2005
17. Fossa SD, Aass N, Harvei S, et al: Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 90:607-612, 2004
18. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513-1523, 2003
19. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000
20. Warde PR, Chung P, Sturgeon J, et al: Should surveillance be considered the standard of care in stage I seminoma? J Clin Oncol 23:382s, 2005 (suppl; abstr 4520)
21. Schmoll HJ, Souchon R, Krege S, et al: European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15:1377-1399, 2004